The bioscience technology sector continues to evolve, being a dynamic field which employs life processes to practical uses, such as new bioscience procedures and advanced drugs in treating viral diseases. The large and emerging volume of industry research indicates future growth within the sector. Companies from across the field have been investing in cancer research, trying to reinvent cancer therapy. Spotlight Innovation Inc. (OTCMKTS: STLT), Immune Pharmaceuticals Inc (NASDAQ: IMNP), NewLink Genetics Corp. (NASDAQ: NLNK), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Agenus Inc. (NASDAQ: AGEN)
Recently, bioscience company Spotlight Innovation Inc. (OTC: STLT) has entered into a sponsored research agreement with Florida State University to battle against the Zika virus; a virus transmitted by Aedes mosquitos that currently has no cure or specific treatment. Spotlight will be supporting FSU professor, Hengli Tang to create harmless yet effective medicine to treat patients who are infected with the virus. The company’s innovation focuses on identifying and acquiring rights to proprietary technologies in areas of unmet medical need, highlighting on rare or emerging diseases and conditions such as Zika.
Spotlight Innovation Inc. (STLT) classifies and acquires rights to innovative, proprietary technologies intended to address unmet medical needs and focuses importantly on unique, emerging and neglected diseases. In order to find and assess extraordinary opportunities, the company strictly leverages their extensive relationships with well-known scientists, top academic institutions and other leading sources. This April Spotlight Innovation achieves key laboratory benchmark for Its Immunoplex™ Immunotherapy Cancer Vaccine Technology.
Spotlight Innovation Inc. (STLT) earlier in the month announced that, Cassandra K. MacArthur has joined the company as Senior Vice President of Regulatory Affairs and Compliance. Ms. MacArthur will be responsible for all aspects of regulatory affairs including strategic planning for regulatory approvals, preparation of regulatory submissions, serving as the primary contact with the FDA and other regulatory authorities, and compliance with all regulatory agencies worldwide.
NewLink Genetics Corporation (NASDAQ: NLNK) is a biopharmaceutical company focused on discovering, developing and commercializing immuno-oncology products to improve the lives of patients suffering from cancer. NewLink’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system and a clinically advanced product candidate for patients with pancreatic cancer, the Algenpantucel-L.
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. The company’s technology platform, NanomAbs, is a platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) has reported positive sales last quarter of the company’s first commercial product, ONIVYDE, a drug that treats patients with metastatic pancreatic cancer. The company specified sales increased by 29% compared to its first quarter, making it at $12.9 million. Merrimack aims to reduce the uncertainty in drug development and clinical validation, and move discovery efforts past trial and error. This approach could make individualized treatment of patients a reality.
Agenus Inc. (NASDAQ: AGEN) has completed enrollment of the first cohort of patients in its Phase 1 study an anti-CTLA-4 antibody (AGEN1884), which was launched earlier in this year. Agenus also plans to initiate clinical studies for a second anti-CTLA-4 antibody, the AGEN2041, in 2017 and thus combine trials with AGEN1884 during its first half of next year. Agenus is an immuno-oncology company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines.